Journal
CANCERS
Volume 13, Issue 6, Pages -Publisher
MDPI
DOI: 10.3390/cancers13061418
Keywords
electrochemotherapy; cisplatin; bleomycin; head and neck cancer; immunotherapy; quality of life
Categories
Ask authors/readers for more resources
Electrochemotherapy (ECT) is a new treatment modality for head and neck cancer, combining locally applied electric pulses with antineoplastic agents. It has shown promising efficacy and tolerable safety profile in clinical studies, making it a potential strategy for heavily pre-treated HNC patients. Efforts to improve its efficacy and expand its application are ongoing, with the combination of ECT with novel therapies like immune checkpoint inhibitors showing theoretical promise. Extensive, well-organized clinical studies and updated consensus guidelines are needed to bring this hopeful treatment to challenging situations in HNC patients.
Simple Summary Electrochemotherapy (ECT) was first introduced in the late 1980s and was initially used mainly on cutaneous tumors. It has now evolved into a clinically verified treatment approach. Thanks to its high feasibility, it has been extended to treating mucosal and deep-seated tumors, including head and neck cancer (HNC) and in heavily pretreated settings. This review describes current knowledge and data on the use of ECT in various forms of HNCs across different clinical settings, with attention to future clinical and research perspectives. Despite recent advances in the development of chemotherapeutic drug, treatment for advanced cancer of the head and neck cancer (HNC) is still challenging. Options are limited by multiple factors, such as a prior history of irradiation to the tumor site as well as functional limitations. Against this background, electrochemotherapy (ECT) is a new modality which combines administration of an antineoplastic agent with locally applied electric pulses. These pulses allow the chemotherapeutic drug to penetrate the intracellular space of the tumor cells and thereby increase its cytotoxicity. ECT has shown encouraging efficacy and a tolerable safety profile in many clinical studies, including in heavily pre-treated HNC patients, and is considered a promising strategy. Efforts to improve its efficacy and broaden its application are now ongoing. Moreover, the combination of ECT with recently developed novel therapies, including immunotherapy, represented by immune checkpoint inhibitor (ICI)s, has attracted attention for its potent theoretical rationale. More extensive, well-organized clinical studies and timely updating of consensus guidelines will bring this hopeful treatment to HNC patients under challenging situations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available